Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma

[1]  Subbaya Subramanian,et al.  Distinct mechanisms of PTEN inactivation in dogs and humans highlight convergent molecular events that drive cell division in the pathogenesis of osteosarcoma. , 2023, Cancer genetics.

[2]  E. Bartee,et al.  The use of oncolytic virotherapy in the neoadjuvant setting , 2022, Journal for ImmunoTherapy of Cancer.

[3]  L. Mirabello,et al.  Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017 , 2022, Cancer.

[4]  D. Dingli,et al.  Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma , 2022, Blood advances.

[5]  B. V. Van Tine,et al.  Truly Man's Best Friend: Canine Cancers Drive Drug Repurposing in Osteosarcoma. , 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H. Kaufman.  Can Biomarkers Guide Oncolytic Virus Immunotherapy? , 2021, Clinical Cancer Research.

[7]  Lu Xie,et al.  The Clinical Implications of Tumor Mutational Burden in Osteosarcoma , 2021, Frontiers in Oncology.

[8]  T. Fan,et al.  Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs , 2021, Clinical Cancer Research.

[9]  A. Mutsaers,et al.  Recent and current clinical trials in canine appendicular osteosarcoma. , 2020, The Canadian veterinary journal = La revue veterinaire canadienne.

[10]  J. Modiano,et al.  Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review , 2019, Veterinary sciences.

[11]  M. Sydes,et al.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.

[12]  Marcus R. Breese,et al.  Genome-Informed Targeted Therapy for Osteosarcoma. , 2018, Cancer discovery.

[13]  Voichita D. Marinescu,et al.  SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. , 2018, Cancer research.

[14]  S. Russell,et al.  Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. , 2018, Cancer cell.

[15]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction , 2018, ArXiv.

[16]  Natalie K. Wolf,et al.  Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma. , 2018, Cancer research.

[17]  S. Russell,et al.  Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer , 2017, Molecular Cancer Therapeutics.

[18]  J. Suzich,et al.  Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  S. Russell,et al.  Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS. , 2016, Human gene therapy. Clinical development.

[20]  N. Lazar,et al.  The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .

[21]  M. Kiupel,et al.  Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma , 2015, PloS one.

[22]  S. Russell,et al.  Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. , 2013, Human gene therapy. Clinical development.

[23]  K. Bailey,et al.  Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters , 2013, PloS one.

[24]  S. Russell,et al.  Curative one-shot systemic virotherapy in murine myeloma , 2012, Leukemia.

[25]  S. Russell,et al.  Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta , 2012, Cancer Gene Therapy.

[26]  J. Cashy,et al.  466 INCIDENCE AND OUTCOMES OF DUCTAL CARCINOMA OF THE PROSTATE: ANALYSIS OF DATA FROM THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM , 2011 .

[27]  S. Russell,et al.  Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways , 2009, Expert opinion on biological therapy.

[28]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[29]  G. Barber,et al.  Development of Recombinant Vesicular Stomatitis Viruses That Exploit Defects in Host Defense To Augment Specific Oncolytic Activity , 2003, Journal of Virology.

[30]  Nahum Sonenberg,et al.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus , 2000, Nature Medicine.

[31]  A. Ryan.  Russell , 1996 .